Related Experiment Video
Updated: Jun 2, 2026
05:33
Ear Plaster Therapy as a Safe and Effective Treatment for Gestational Vomiting
Published on: August 4, 2023
[Mirtazapine and hyperemesis gravidarum]
1Konsiliardienst Psychiatrie, Psychotherapie und Psychosomatik, Klinik für Psychiatrie und Psychotherapie, Ludwig-Maximilians-Universität, Campus Innenstadt, Nussbaumstr. 7, 80336, München, Deutschland. martin.lieb@med.uni-muenchen.de
Der Nervenarzt
|May 13, 2011
Summary
Severe nausea and vomiting in pregnancy (hyperemesis gravidarum) unresponsive to standard treatments improved with mirtazapine. This case highlights mirtazapine as a potential treatment option for refractory hyperemesis gravidarum.
Area of Science:
- Obstetrics and Gynecology
- Pharmacology
- Clinical Case Studies
Background:
- Hyperemesis gravidarum (HG) is a severe form of nausea and vomiting during pregnancy.
- Conventional antiemetic therapies are often insufficient for managing severe HG cases.
- Refractory HG poses significant risks to both maternal and fetal health.
Observation:
- A 29-year-old patient at 21 weeks gestation presented with severe hyperemesis gravidarum.
- The patient's symptoms did not improve with standard antiemetic medications.
- Intravenous administration of mirtazapine (30 mg/day) was initiated.
Findings:
- Significant improvement in nausea and vomiting was observed within 48 hours of mirtazapine administration.
- Mirtazapine effectively managed the severe symptoms of hyperemesis gravidarum in this case.
- The patient tolerated the treatment well, with symptom resolution.
Implications:
- Mirtazapine may represent a viable therapeutic option for severe, treatment-resistant hyperemesis gravidarum.
- Further research is warranted to establish the efficacy and safety profile of mirtazapine in HG.
- This case contributes to understanding alternative pharmacological interventions for managing complex pregnancy-related conditions.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...